CONCOMITANT INHIBITION OF EZH1 AND EZH2 IMPAIRS GROWTH OF C-MYC DRIVEN B CELL LYMPHOMAS

被引：0
|
作者：
Petrocelli, V. [1 ]
Varano, G. [1 ]
Carrisi, C. [1 ]
Rahmat, M. [1 ]
Zanardi, F. [1 ]
Jin, J. [2 ]
Casola, S. [1 ]
机构：
[1] IFOM Fdn, FIRC Inst Mol Oncol, Milan, Italy
[2] Univ N Carolina, Chapel Hill, NC USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P420
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [41] Analysis of c-MYC, EZH2, and Ki-67 in Primary Diffuse Large B Cell Lymphoma (DLBCL) of the Gastrointestinal Tract
    Luria, L.
    Nguyen, J.
    Zhou, J.
    Coppola, D.
    Messina, J.
    Zhang, L.
    LABORATORY INVESTIGATION, 2014, 94 : 359A - 359A
  • [42] Analysis of c-MYC, EZH2, and Ki-67 in Primary Diffuse Large B Cell Lymphoma (DLBCL) of the Gastrointestinal Tract
    Luria, L.
    Nguyen, J.
    Zhou, J.
    Coppola, D.
    Messina, J.
    Zhang, L.
    MODERN PATHOLOGY, 2014, 27 : 359A - 359A
  • [43] Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2
    Lau-Corona, Dana
    Bae, Woo Kyun
    Hennighausen, Lothar
    Waxman, David J.
    PLOS GENETICS, 2020, 16 (05):
  • [44] Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas
    Tian, Xuejun
    Xu, Jie
    Dorfman, David M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (01) : 102 - 109
  • [45] EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL)
    Garcia, M.
    Fernandez-Rodriguez, C.
    Casado, B.
    Baro, M.
    Puiggros, A.
    Salido, M.
    Alamo, A.
    Gimeno, E.
    Sanchez-Gonzalez, B.
    Espinet, B.
    Serrano, S.
    Salar, A.
    Bellosillo, B.
    HAEMATOLOGICA, 2013, 98 : 350 - 350
  • [46] Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
    Bisserier, Malik
    Wajapeyee, Narendra
    BLOOD, 2018, 131 (19) : 2125 - 2137
  • [47] EZH2 inhibition targets B7-H3 in Myc amplified medulloblastoma
    Shishido, Katherine
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    Velpula, Kiran
    Asuthkar, Swapna
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Low and High Grade B-Cell Non-Hodgkin Lymphomas and Differential Regulation of EZH2 Expression By p-ERK and MYC in High Grade B Cell Lymphomas
    Tian, Xuejun
    Shahsafaei, Ali
    Dorfman, David M.
    BLOOD, 2015, 126 (23)
  • [49] Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
    Oaknin, A.
    Drescher, C.
    Banda, K.
    Duska, L.
    Ribrag, V.
    Tewari, A.
    Lakhani, N. J.
    Eberst, L.
    Harvey, R. D.
    Sanchez, L. M. Manso
    Lorusso, D.
    Kindler, H.
    Walter, H. S.
    Illescas, D. G.
    Pons-Tostivint, E.
    Thakur, A. G.
    Kann, L.
    Reddy, A.
    Faulhaber, N.
    Gonzalez-Martin, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S567 - S568
  • [50] Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
    Honma, Daisuke
    Kanno, Osamu
    Watanabe, Jun
    Kinoshita, Junzo
    Hirasawa, Makoto
    Nosaka, Emi
    Shiroishi, Machiko
    Takizawa, Takeshi
    Yasumatsu, Isao
    Horiuchi, Takao
    Nakao, Akira
    Suzuki, Keisuke
    Yamasaki, Tomonori
    Nakajima, Katsuyoshi
    Hayakawa, Miho
    Yamazaki, Takanori
    Yadav, Ajay Singh
    Adachi, Nobuaki
    CANCER SCIENCE, 2017, 108 (10): : 2069 - 2078
12345